Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 14/20 | 0.58 |
| ▸ | EDNRA | P25101 | 6/20 | 0.46 |
| ▸ | EDNRB | P24530 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770374 | 1.00 | DHPS (0.58) | DHPSEDNRAEDNRB | |
| SCHEMBL7795451 | 0.91 | DHPS (0.53) | DHPSEDNRAEDNRB | |
| SCHEMBL1257596 | 0.90 | DHPS (0.52) | DHPSEDNRAEDNRB | |
| SCHEMBL4064097 | 0.90 | DHPS (0.74) | DHPS | |
| SCHEMBL3227293 | 0.90 | DHPS (0.51) | DHPSEDNRAEDNRB | |
| SCHEMBL9423908 | 0.87 | LMNA (0.55) | DHPS | |
| SCHEMBL7300009 | 0.86 | DHPS (0.51) | DHPSEDNRA | |
| SCHEMBL4062097 | 0.86 | DHPS (0.51) | DHPSEDNRAEDNRB | |
| SCHEMBL13430565 | 0.85 | DHPS (0.43) | DHPSEDNRAEDNRB | |
| SCHEMBL7787027 | 0.85 | EDNRA (0.53) | DHPSEDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907275-A | Preparation method of bosentan | 武汉工程大学 | 2022-08-16 | — | — | CN | claimed |
| EP-2603497-B1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | MEGAFINE PHARMA P LTD (IN) | 2018-08-08 | — | — | EP | claimed |
| US-20130296560-A1 | Novel Process For Preparation Of Bosentan | MEGAFINE PHARMA (P) LTD. (IN) | 2013-11-07 | — | — | US | claimed |
| EP-2603497-A1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | Megafine Pharma (P) Ltd. (IN) | 2013-06-19 | — | — | EP | claimed |
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2012-05-31 | — | — | US | claimed |
| EP-2419421-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | Sandoz AG (CH) | 2012-02-22 | — | — | EP | claimed |
| WO-2012020421-A1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | MEGAFINE PHARMA (P) LTD. (IN) | 2012-02-16 | — | — | WO | claimed |
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2331513-A1 | PROCESS FOR PREPARATION OF BOSENTAN | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | claimed |
| WO-2010118992-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2010-10-21 | — | — | WO | claimed |
| EP-2240470-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN Laboratories Limited (IN) | 2010-10-20 | — | — | EP | claimed |
| WO-2009095933-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | claimed |
| EP-0841326-B1 | Process for the preparation of pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2001-05-16 | — | — | EP | claimed |
| US-6121447-A | STARTING WITH 2-CYANOPYRIMIDINE, WHICH IS PREPARED BY REACTING 2-CHLOROPYRIMIDINE WITH AN ALKALI CYANIDE IN THE PRESENCE OF 1-AZABICYCLO(2,2,2)OCTANE OR 1,4-DIAZABICYCLO(2,2,2)OCTANE | HOFFMANN-LA ROCHE INC. (US) | 2000-09-19 | — | — | US | claimed |
| EP-0841326-A1 | Process for the preparation of pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-13 | — | — | EP | claimed |
| CN-114605337-B | Preparation method of high-purity bosentan | 重庆医药高等专科学校 | 2024-03-12 | — | — | CN | disclosed |
| CN-114605337-B | Preparation method of high-purity bosentan | 重庆医药高等专科学校 | 2024-03-12 | — | — | CN | disclosed |
| EP-0601386-A1 | Sulphonamides | F. HOFFMANN-LA ROCHE AG (CH) | 1994-06-15 | — | — | EP | disclosed |
| US-5292740-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0526708-A1 | Sulfonamide, preparation and use thereof as medicine and intermediate | F. HOFFMANN-LA ROCHE AG (CH) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CYP2D6, CYP3A5, QDPR | DHPS 5/4885EDNRA 146/4885EDNRB 13/4885 |
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | EDNRA, EDNRB, TBXA2R | DHPS 400/4885EDNRA 1/4885EDNRB 2/4885 |
| US-20130296560-A1 | Novel Process For Preparation Of Bosentan | BMP6, EDNRB, PAH | DHPS 153/4885EDNRA 9/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.